Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | PLAU | P00749 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16975385 | 0.93 | ACHE (0.45) | F2PLAUELANEL3MBTL1ACHE | |
| SCHEMBL16974776 | 0.93 | ACHE (0.42) | F2PLAUELANEL3MBTL1ACHE | |
| SCHEMBL17199452 | 0.92 | F2 (0.39) | F2PLAUELANEL3MBTL1ACHE | |
| SCHEMBL18761846 | 0.92 | F2 (0.39) | F2PLAUELANEL3MBTL1ACHE | |
| SCHEMBL17199450 | 0.92 | F2 (0.39) | F2PLAUELANEL3MBTL1ACHE | |
| SCHEMBL21296363 | 0.91 | L3MBTL1 (0.45) | F2PLAUELANEL3MBTL1ACHE | |
| SCHEMBL16196214 | 0.91 | MEN1 (0.42) | F2PLAUELANEL3MBTL1ACHE | |
| SCHEMBL1559387 | 0.89 | ALDH1A1 (0.39) | F2PLAUELANEL3MBTL1ALDH1A1 | |
| SCHEMBL16975322 | 0.89 | MPO (0.48) | F2PLAUELANEL3MBTL1ACHE | |
| SCHEMBL15709846 | 0.89 | CYP1A2 (0.43) | F2PLAUELANECYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103873-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 杭州百新生物医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-12624023-B2 | Sulfonylurea derivatives and uses thereof | NodThera Limited (GB) | 2026-05-12 | — | — | US | disclosed |
| EP-4720060-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2026-04-08 | — | — | EP | disclosed |
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-20260035375-A1 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2026-02-05 | — | — | US | disclosed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | disclosed |
| EP-3983407-B1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | NODTHERA LTD (GB) | 2025-11-12 | — | — | EP | disclosed |
| US-12459952-B2 | TREM2 modulators | MUNA THERAPEUTICS APS (DK) | 2025-11-04 | — | — | US | disclosed |
| US-12459925-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NodThera Limited (GB) | 2025-11-04 | — | — | US | disclosed |
| CN-103189369-A | Pyridone/pyrazinones, methods of making, and methods of use thereof | GILEAD CONNECTICUT INC | 2013-07-03 | — | — | CN | disclosed |
| US-8436001-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-07 | — | — | US | disclosed |
| WO-2013045461-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| EP-2556066-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-02-13 | — | — | EP | disclosed |
| CN-102933572-A | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | HOFFMANN LA ROCHE | 2013-02-13 | — | — | CN | disclosed |
| WO-2012031004-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031004-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011124580-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-13 | — | — | WO | disclosed |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, SNCA | F2 4820/4885PLAU 4756/4885ELANE 4545/4885 |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | F2 2986/4885PLAU 2496/4885ELANE 4458/4885 |
| US-12459952-B2 | TREM2 modulators | FCER2, MERTK, FCGR1A | F2 3895/4885PLAU 2033/4885ELANE 1185/4885 |
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK1, JAK3, JAK2 | F2 2257/4885PLAU 4097/4885ELANE 4677/4885 |
| US-12624023-B2 | Sulfonylurea derivatives and uses thereof | PYCARD, NOD1, NLRP3 | F2 3141/4885PLAU 1825/4885ELANE 818/4885 |
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | F2 3009/4885PLAU 2693/4885ELANE 4325/4885 |
| US-20260035375-A1 | TREM2 MODULATORS | MSR1, CSF1R, CX3CR1 | F2 4457/4885PLAU 3445/4885ELANE 804/4885 |
| US-12459925-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NLRP3, NOD1, IL1B | F2 4213/4885PLAU 1778/4885ELANE 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.